{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T08:24:43Z","timestamp":1749889483664,"version":"3.37.3"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-022-03300-7","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:03:06Z","timestamp":1658217786000},"page":"167-171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hypoxia inducible factor-prolyl hydroxylase inhibitors in anemic patients with non-dialysis dependent chronic kidney disease: a meta-analysis of randomized clinical trials"],"prefix":"10.1007","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-7811","authenticated-orcid":false,"given":"Mohamed M. G.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosunmoluwa","family":"Oyenuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safia","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abayomi","family":"Oyenuga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Babikir","family":"Kheiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Nwankwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,19]]},"reference":[{"issue":"2","key":"3300_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10157-017-1468-8","volume":"22","author":"Y Sato","year":"2018","unstructured":"Sato Y, Fujimoto S, Konta T et al (2018) Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease. Clin Exp Nephrol 22(2):388\u2013394. https:\/\/doi.org\/10.1007\/s10157-017-1468-8","journal-title":"Clin Exp Nephrol"},{"key":"3300_CR2","unstructured":"Research C for DE and FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease. FDA. Published online January 5 2021. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis. Accessed 9 May 2021"},{"issue":"6","key":"3300_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB (2017) Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis 69(6):815\u2013826. https:\/\/doi.org\/10.1053\/j.ajkd.2016.12.011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"3300_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","volume":"11","author":"VH Haase","year":"2021","unstructured":"Haase VH (2021) Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int 11(1):8\u201325. https:\/\/doi.org\/10.1016\/j.kisu.2020.12.002","journal-title":"Kidney Int"},{"issue":"1","key":"3300_CR5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/ckj\/sfy013","volume":"12","author":"L Holdstock","year":"2019","unstructured":"Holdstock L, Cizman B, Meadowcroft AM et al (2019) Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J 12(1):129\u2013138. https:\/\/doi.org\/10.1093\/ckj\/sfy013","journal-title":"Clin Kidney J"},{"issue":"1","key":"3300_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T (2019) Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol 14(1):28\u201339. https:\/\/doi.org\/10.2215\/CJN.02510218","journal-title":"Clin J Am Soc Nephrol"},{"key":"3300_CR7","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020091311","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y et al (2021) Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.2020091311 (Published online April 21, 2021:ASN.2020091311)","journal-title":"J Am Soc Nephrol"},{"issue":"17","key":"3300_CR8","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK et al (2021) Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384(17):1589\u20131600. https:\/\/doi.org\/10.1056\/NEJMoa2035938","journal-title":"N Engl J Med"},{"issue":"1","key":"3300_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513103","volume":"52","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Hamano T, Akizawa T et al (2021) Daprodustat compared with epoetin beta pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. Am J Nephrol 52(1):26\u201335. https:\/\/doi.org\/10.1159\/000513103","journal-title":"Am J Nephrol"},{"issue":"25","key":"3300_CR10","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV et al (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385(25):2313\u20132324. https:\/\/doi.org\/10.1056\/NEJMoa2113380","journal-title":"N Engl J Med"},{"issue":"4","key":"3300_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000502012","volume":"143","author":"T Akizawa","year":"2019","unstructured":"Akizawa T, Macdougall IC, Berns JS et al (2019) Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor patients with chronic kidney disease. Nephron 143(4):243\u2013254. https:\/\/doi.org\/10.1159\/000502012","journal-title":"Nephron"},{"issue":"4","key":"3300_CR12","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/jcpt.13385","volume":"46","author":"H Chen","year":"2021","unstructured":"Chen H, Cheng Q, Wang J, Zhao X, Zhu S (2021) Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients. J Clin Pharm Ther 46(4):999\u20131009. https:\/\/doi.org\/10.1111\/jcpt.13385","journal-title":"J Clin Pharm Ther"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03300-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-022-03300-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-022-03300-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T11:43:46Z","timestamp":1672659826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-022-03300-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,19]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1007\/s11255-022-03300-7","relation":{},"ISSN":["1573-2584"],"issn-type":[{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2022,7,19]]},"assertion":[{"value":"4 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests:","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}